finance.yahoo.com
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and treatment response if later trials are positive.
Adults with Crohn’s disease and clinicians who monitor disease activity; researchers and imaging specialists following IBD diagnostics.
What To Know
Summary eligible: yes What to know The FDA has granted fast track designation to Bracco Imaging’s ultrasound contrast agent BR55 for detecting active bowel inflammation in Crohn’s disease. BR55 is a VEGFR2-targeted microbubble agent being developed to improve ultrasound signal and help identify angiogenesis and active inflammation without radiation.
Bracco plans larger Phase III trials after earlier-phase studies and prior cancer tissue work. How it might matter If subsequent trials confirm accuracy and safety, BR55 could become a non-invasive imaging option for monitoring disease activity and treatment response in Crohn’s disease, potentially reducing reliance on procedures that use radiation.
Fast track status means the FDA sees it as addressing an unmet need and may accelerate review, but it is not an approval. Limitations and next steps The news reports completed Phase II work and plans for controlled Phase III studies; Phase III results and regulatory approval are still needed.
The article summarizes industry and company statements and does not provide detailed trial data, safety outcomes, or timelines.
Fast track designation expedites development and review but is not an approval. The article refers to Phase II and planned Phase III studies; readers should wait for peer-reviewed trial results and regulatory decisions before inferring clinical impact.
